What do we know about the antibody responses to SARS-CoV-2?

被引：27
|
作者：
Alejandro Lagunas-Rangel, Francisco [1 ]
Chavez-Valencia, Venice [2 ]
机构：
[1] Inst Politecn Nacl CINVESTAV, Dept Genet & Mol Biol, Ctr Invest & Estudios Avanzados, Mexico City, DF, Mexico
[2] Hosp Gen Reg Hosp 1, Inst Mexicano Seguro Social, Dept Nephrol, Morelia, Michoacan, Mexico
来源：
IMMUNOBIOLOGY | 2021年 / 226卷 / 02期
关键词：
COVID-19; Humoral response; Seroconversion; Convalescent plasma; NEUTRALIZING ANTIBODIES;
D O I：
10.1016/j.imbio.2021.152054
中图分类号：
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号：
100102 ;
摘要：
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has spread worldwide causing a pandemic with millions of infected people and deaths. Currently, the scientific community is working hard to develop a specific vaccine or treatment. However, since antibody production is an important part of the adaptive immune response, to develop vaccines and therapies, we must understand the antibody response to SARS-CoV-2 infection. In this work, we summarize the most important findings of antibody-mediated immunity against SARS-CoV-2 and highlight its role in the efficient use of plasma from convalescent patients and the direct application of antibodies as treatment.
引用
收藏
页数：6
相关论文
共 50 条
  • [1] What do we know about the function of SARS-CoV-2 proteins?
    Arevalo, Santiago Justo
    Castillo-Chavez, Adriana
    Calampa, Carmen Sofia Uribe
    Sifuentes, Daniela Zapata
    Huallpa, Cesar J.
    Bianchi, Gianfranco Landa
    Casas, Romina Garavito-Salini
    Aguilar, Mauro Quinones
    Chavarria, Roberto Pineda
    [J]. FRONTIERS IN IMMUNOLOGY, 2023, 14
  • [2] What do we know about the SARS-CoV-2 coronavirus in the environment?
    Nunez-Delgado, Avelino
    [J]. SCIENCE OF THE TOTAL ENVIRONMENT, 2020, 727
  • [3] What we know and what we need to know about the origin of SARS-CoV-2
    Domingo, Jose L.
    [J]. ENVIRONMENTAL RESEARCH, 2021, 200
  • [4] Virus interactions with the actin cytoskeleton—what we know and do not know about SARS-CoV-2
    Malgorzata Kloc
    Ahmed Uosef
    Jarek Wosik
    Jacek Z. Kubiak
    Rafik M. Ghobrial
    [J]. Archives of Virology, 2022, 167 : 737 - 749
  • [5] SARS-CoV-2 and the Brain: What Do We Know about the Causality of 'Cognitive COVID?
    Ali Awan, Hashir
    Najmuddin Diwan, Mufaddal
    Aamir, Alifiya
    Ali, Muneeza
    Di Giannantonio, Massimo
    Ullah, Irfan
    Shoib, Sheikh
    De Berardis, Domenico
    [J]. JOURNAL OF CLINICAL MEDICINE, 2021, 10 (15)
  • [6] Drugs against SARS-CoV-2: What do we know about their mode of action?
    Valle, Coralie
    Martin, Baptiste
    Touret, Franck
    Shannon, Ashleigh
    Canard, Bruno
    Guillemot, Jean-Claude
    Coutard, Bruno
    Decroly, Etienne
    [J]. REVIEWS IN MEDICAL VIROLOGY, 2020, 30 (06) : 1 - 10
  • [7] Cytokines and microRNAs in SARS-CoV-2: What do we know?
    Rarani, Fahimeh Zamani
    Rashidi, Bahman
    Abadi, Mohammad Hassan Jafari Najaf
    Hamblin, Michael R.
    Hashemian, Seyed Mohammad Reza
    Mirzaei, Hamed
    [J]. MOLECULAR THERAPY NUCLEIC ACIDS, 2022, 29 : 219 - 242
  • [8] SARS-CoV-2: What do we know so far?
    Khedkar, Pratik H.
    Patzak, Andreas
    [J]. ACTA PHYSIOLOGICA, 2020, 229 (02)
  • [9] Hearing Loss in SARS-CoV-2: What Do We Know?
    Saniasiaya, Jeyasakthy
    [J]. ENT-EAR NOSE & THROAT JOURNAL, 2021, 100 (2_SUPPL) : 152S - 154S
  • [10] Virus interactions with the actin cytoskeleton-what we know and do not know about SARS-CoV-2
    Kloc, Malgorzata
    Uosef, Ahmed
    Wosik, Jarek
    Kubiak, Jacek Z.
    Ghobrial, Rafik M.
    [J]. ARCHIVES OF VIROLOGY, 2022, 167 (03) : 737 - 749
12345